ADHD

The Pharmacy Times® ADHD resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.

What can we help you find?
[[thumbnail_alt_text]]
It is critical to stress that Attention-Deficit/Hyperactivity Disorder is probably a lifelong condition for most individuals with the condition.
[[thumbnail_alt_text]]
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.
[[thumbnail_alt_text]]
The prescription of stimulants for the treatment of attention deficit-hyperactivity disorder (ADHD) is increasing among adolescents and young adults, and a new study sheds light on possible safety concerns.
[[thumbnail_alt_text]]
The drug's approval was based on 4 clinical studies evaluating the efficacy and safety of Adhansia XR in 883 people who met DSM-5 criteria for ADHD.  
[[thumbnail_alt_text]]
Within the group of Spanish patients with ADHD, a specific variation of the LPHN3 gene increased by 40% the risk of nicotine dependence.
[[thumbnail_alt_text]]
Under the settlement and license agreement, Neos has granted Teva the right to manufacture and market its generic version of Cotempla XR-ODT® under the Teva ANDA beginning on July 1, 2026, or earlier under certain circumstances.
[[thumbnail_alt_text]]
Canine animal assistance improves attentiveness and social skills in children with ADHD, according to recent study.
[[thumbnail_alt_text]]
A recent study found that athletes with attention deficit hyperactivity disorder (ADHD) may need to be even more cautious in concussion prevention.
[[thumbnail_alt_text]]
Both asthma and attention-deficit/hyperactivity disorder (ADHD), both chronic conditions, have been associated with each other in previous studies, but questions remained as to the strength of the association because of other possible confounders.
[[thumbnail_alt_text]]
New research suggests psychiatric diseases that affect a patient’s ability to appropriately respond to stimuli may be triggered by the misplacement of an enzyme in the pathway within neurons.
[[thumbnail_alt_text]]
New research suggests psychiatric diseases, including ADHD, that affect a patient’s ability to appropriately respond to stimuli may be triggered by the misplacement of an enzyme in the pathway within neurons.